<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180521039763N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-04</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Acetaminophen-Ibuprofen combination on pain relief regarding the prescription time</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of  Acetaminophen-Ibuprofen combination on pain relief following primary tooth extraction regarding the prescription time in 6-12 year old children in Kerman,Iran</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/36962</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The Random allocation rule has been used.(Reference:Mohammadi M, Janani L. Randomization in randomized clinical Trials: 
from theory to practice). 
Based on the number of participants, provide one form and we have 120 forms totally which putting in on file.Then according to the patient entrance,
 one of the forms will be raised consecutively, Blinding description: Acetaminophen-Ibuprofen  combination or placebo(Neurobion forte-vit B Complex vita B12) in form of syrup will be given to each group.

Each child will have a code and will be known with this code in information form.
 Analyzer will analysis data according to these codes.</study_design>
      <phase>3</phase>
      <hc_freetext>The effect of Acetaminophen-Ibuprofen combination on   relieving pain before and after extraction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: First group, 1 hour before extraction, dose of Acetaminophen-Ibuprofen will be indicated according to exact weight which will be calculated with digital scale .(Personal Scale Business counting Digital Scale,KG180) Ibuprofen suspension( Ibuprofen,Alborzrdarou Co,Iran 100mg/5ml Susp) in dose of 2.5mg/kg and Acetaminophen syrup( Acetaminophen, syrup,60mg/5ml, Ramofarmin Co,Iran)in dose of 7.5mg/kg  will be calculated. Second group: 1 hour after extraction, dose of Acetaminophen-Ibuprofen combination similar to first group will be calculated and indicated. Intervention 2: Control group:First group, placebo as  syrup(Neurobion forte-vit B lComplex vita B12, OTC Pharmaceutical Products. www.otcpharmausa) 16 Oz,/ 473ml with the same dose of Acetaminophen-Ibuprofen combination will be indicated one hour before extraction.Second group: one hour after extraction will be given.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is shared by non-identifiable participants

When:
6 months after printing result

To whom:
People working in academic centers

Conditions:
The use of information is permitted for more comprehensive research

Where to obtain:
Shokrizadeh Mahboobeh, Jahanimoghadam Fatemeh

How to obtain:
After reviewing the request masseage, information is provided to them

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Jahanimoghadam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shafa Ave, Jomhuri Blvd</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618819949</zip>
        <telephone>+98 34 3211 8071</telephone>
        <email>Fatemehjahani4@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Jahanimoghadam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shafa Ave, Jomhuri Blvd</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618819949</zip>
        <telephone>+98 34 3212 7557</telephone>
        <email>Fatemehjahani4@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>6-12 year- old children
Without any systemic diseases
The children have sufficient physical  growth and mental development.
Be cooperative</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Children with liver,renal,gastric disorders and colitis
History of corticosteroid  or/and pain reliever use in recent 24 hours.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: First group, 1 hour before extraction, dose of Acetaminophen-Ibuprofen will be indicated according to exact weight which will be calculated with digital scale .(Personal Scale Business counting Digital Scale,KG180) Ibuprofen suspension( Ibuprofen,Alborzrdarou Co,Iran 100mg/5ml Susp) in dose of 2.5mg/kg and Acetaminophen syrup( Acetaminophen, syrup,60mg/5ml, Ramofarmin Co,Iran)in dose of 7.5mg/kg  will be calculated. Second group: 1 hour after extraction, dose of Acetaminophen-Ibuprofen combination similar to first group will be calculated and indicated.</i_keyword>
      <i_keyword>Control group:First group, placebo as  syrup(Neurobion forte-vit B lComplex vita B12, OTC Pharmaceutical Products. www.otcpharmausa) 16 Oz,/ 473ml with the same dose of Acetaminophen-Ibuprofen combination will be indicated one hour before extraction.Second group: one hour after extraction will be given.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain relief rate. Timepoint: Immediately after extraction until the next 24 hours. Method of measurement: According to Visual Analigue Scale(VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The effect of age,gender on  Acetaminophen-Ibuprofen combination. Timepoint: During filling the questionare. Method of measurement: Age will be calculated according to birth year/Gender aacording to observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-23</approval_date>
        <contact_name>Ethics committee of Kerman university of medical</contact_name>
        <contact_address>Shafa Ave, Jomhuri Blvd Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
